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PLAGL2 (PLAG-Like 2; a PLAG family member; 
GenBank accession number AF006005) was identified 
by homology searches of the database of expressed 
sequence tags (ESTs) and sequence similarity to zinc-





PLAGL2 protein consists of 496 amino acid residues, 
six C2H2-type zinc finger domains in its amino-
terminal region (shown as brown in the figure), and a 
proline- and serine-rich carboxyl terminus (shown as 
blue). 
Expression 
Northern analysis showed that the PLAGL2 mRNA is 
expressed in fetal kidney, liver, lung, and brain but not 
in adult tissues. However, PCR analysis showed that 
PLAGL2 is ubiquitously expressed in almost all adult 
and fetal human tissues, except for the relatively low 




PLAGL2 can bind and activate human insulin-like 
growth factor II (IGF II) gene promoter; therefore, the 
oncogenic capacity of PLAGL2 may be mediated by 
activating the IGF-II mitogenic pathway. However, 
PLAGL2, possibly by association with HIF-1, may also 
have apoptotic role since it can activate Nip3 promoter 
and induce transcription in Balb/c3T3 fibroblasts and 
Neuro2a neuroblastoma cells, leading to apoptosis. 
PLAGL2 mRNA can be induced upon iron deficiency 
or hypoxia in mouse macrophage cell line RAW264.7, 




PLAGL2 exons and corresponding nucleotide numbers on each GenBank sequence database are shown in this table. 










In addition, PLAGL2 can also transactivate the 
surfactant protein-C (SP-C), a protein whose 
expression occurs principally in type II pneumocytes 
located in the distal lung alveolae. Additional data 
suggest that repression of the transactivating capacity 
of PLAGL2 may be directly related to sumoylation. 
Also, PLAGL2 protein is acetylated and activated by 
p300 and deacetylated and repressed by HDAC7, 
involving the lysine residues as the acetylation target. 
Therefore, it appears that the activity of PLAGL2 is 
tightly modulated by both sumoylation and acetylation, 
which may have opposite effects on their 
transactivation. Tip60 can modulate PLAGL2 function 
through both acetylation and inhibition of sumoylation, 
resulting in an enhanced PLAGL2-mediated 
transactivation. PLAGL2 can bind and stabilize (by 
preventing proteasomal degradation) Pirh2 dimer, a 
p53 inducible E3 ligase involved in the ubiquitination 
of p53. PLAGL2 can also regulate NCF2 gene 
expression through binding to the tumor necrosis factor 
(TNF)-alpha-responsive region of the NCF2 promoter, 
thus regulating p67(phox) expression and NADPH 
oxidase activity. PLAGL2 was recently found to aid in 
the efficient uptake of chylomicrons by intestinal 
lacteal vessels. 
Homology 
Homologous to the human PLAG1 and PLAGL1 
proteins. 
Mutations 




Note: PLAGL2 is an oncoprotein involved in various 
malignancies including lipoblastomas, 
hepatoblastomas, and acute myeloid leukemia. 
PLAGL2 expression is increased in human cancers 
including acute myeloid leukemia (AML). The 
expression is increased in 20% of human AML 
samples. The PLAGL2 gene can independently 
cooperate with CBFB-MYH11 fusion gene in 
leukemogenesis. AML subtype M4 with eosinophilia is 
associated with a chromosome 16 inversion that creates 
a fusion gene CBFB-MYH11, encoding CBFbeta-
SMMHC fusion protein. This fusion protein inhibits the  
core-binding factor (CBF), resulting in a block of 
hematopoietic differentiation and induction of leukemia 
in the presence of additional mutations. 
Disease 
Cancer; lipoblastomas, hepatoblastomas, and acute 
myeloid leukemia. 
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